Here, after balancing sociodemographic and clinical covariates, we found that patients with DM and treated for HT exhibited a higher frequency of healthcare visits associated with stroke/TIA, more visits with specialty care providers, and received a greater number of prescriptions for CVD-related medications (SGLT-2 inhibitors, diuretics, beta-blockers, and cholesterol-lowering medications). The gene discussed is SLC5A2; the disease is transient ischemic attack.